keyword
MENU ▼
Read by QxMD icon Read
search

Ticagrelor

keyword
https://www.readbyqxmd.com/read/29243114/effect-of-cytochrome-p450-2c19-polymorphism-on-adverse-cardiovascular-events-after-drug-eluting-stent-implantation-in-a-large-hakka-population-with-acute-coronary-syndrome-receiving-clopidogrel-in-southern-china
#1
Zhixiong Zhong, Jingyuan Hou, Qifeng Zhang, Bin Li, Cunren Li, Zhidong Liu, Min Yang, Wei Zhong, Xuebo He, Hesen Wu, Miaocai Zhong, Pingsen Zhao
BACKGROUND AND OBJECTIVES: The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China. METHODS: Genotyping of CYP2C19 and MACE of 934 ACS patients with PCI on clopidogrel maintenance therapy were analyzed...
December 14, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29240872/worldwide-reporting-of-fatal-outcomes-after-ticagrelor-to-the-us-food-and-drug-administration
#2
Victor L Serebruany, Moo Hyun Kim, Thomas A Marciniak
No abstract text is available yet for this article.
December 11, 2017: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29233189/head-to-head-comparison-of-prasugrel-versus-ticagrelor-in-patients-with-acute-coronary-syndrome-a-systematic-review-and-meta-analysis-of-randomized-trials
#3
Pravesh Kumar Bundhun, Jia-Xin Shi, Feng Huang
BACKGROUND: Prasugrel and Ticagrelor are emerging antiplatelet drugs that might have the potential to replace currently used antiplatelet agents. Previous analyses comparing prasugrel with ticagrelor mainly focused on an indirect comparison whereas direct comparison was reported only in a few recently published trials. We aimed to systematically carry out a head to head comparison of the adverse clinical outcomes which were associated with prasugrel versus ticagrelor in patients with acute coronary syndrome (ACS)...
December 12, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29230546/management-and-predictors-of-outcome-in-unselected-patients-with-cardiogenic-shock-complicating-acute-st-segment-elevation-myocardial-infarction-results-from-the-bremen-stemi-registry
#4
Tina Backhaus, Andreas Fach, Johannes Schmucker, Eduard Fiehn, Daniela Garstka, Janina Stehmeier, Rainer Hambrecht, Harm Wienbergen
INTRODUCTION: Patients with ST-segment elevation myocardial infarction (STEMI) and consecutive cardiogenic shock (CS) represent a challenge in clinical practice. Only few 'real-world' data on therapeutic management and outcome exist. METHODS: The present analysis focuses on changes of clinical management of STEMI-patients with CS and analyzes predictors of outcome using the Bremen-STEMI registry. RESULTS: Out of 7865 patients with STEMI, 981 patients (13%) presented with CS...
December 11, 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/29228817/cangrelor-in-percutaneous-coronary-intervention-current-status-and-perspectives
#5
Dimitrios Alexopoulos, Christos Pappas, Danai Sfantou, John Lekakis
Cangrelor is an intravenously administered P2Y12 receptor antagonist with very fast, potent, and quickly reversible action. In the CHAMPION PHOENIX trial, cangrelor provided an improved anti-ischemic protection compared with clopidogrel, without increasing the risk of severe bleeding. Cangrelor is currently approved by drug regulating authorities for patients undergoing percutaneous coronary intervention (PCI) without prior treatment with a P2Y12 receptor antagonist and not receiving a glycoprotein IIb/IIIa inhibitor, while its use is endorsed with a class IIb recommendation by the European Society of Cardiology guidelines...
January 2018: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29226707/managing-anticoagulation-in-patients-receiving-implantable-cardiac-devices
#6
Panagiota Anna Chousou, Peter J Pugh
A substantial proportion of patients who undergo cardiac device implantation receive oral anticoagulation to prevent thromboembolism or antiplatelets to prevent thrombotic events. Anticoagulation and antiplatelets increase the risk of hemorrhagic complications, while discontinuation may increase thromboembolic risk and thrombotic events. With the introduction of non-vitamin K antagonist oral anticoagulant agents and the newer antiplatelet agents such as prasugrel or ticagrelor, the perioperative management of patients has become more challenging...
December 11, 2017: Future Cardiology
https://www.readbyqxmd.com/read/29225903/early-clinical-outcomes-as-a-function-of-use-of-newer-oral-p2y12-inhibitors-versus-clopidogrel-in-the-euromax-trial
#7
Kurt Huber, Gregory Ducrocq, Christian W Hamm, Arnoud van 't Hof, Frédéric Lapostolle, Pierre Coste, Giovanni Gordini, Jacob Steinmetz, Freek W A Verheugt, Jennifer Adgey, Lutz Nibbe, Vojko Kaniĉ, Peter Clemmensen, Uwe Zeymer, Debra Bernstein, Jayne Prats, Efthymios N Deliargyris, Ph Gabriel Steg
Objective: To ascertain whether different oral P2Y12 inhibitors might affect rates of acute stent thrombosis and 30-day outcomes after primary percutaneous coronary intervention (pPCI). Methods: The European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) randomised trial compared prehospital bivalirudin with heparin with optional glycoprotein IIb/IIIa inhibitor treatment in patients with ST-segment elevation myocardial infarction triaged to pPCI. Choice of P2Y12 inhibitor was at the investigator's discretion...
2017: Open Heart
https://www.readbyqxmd.com/read/29224649/efficacy-and-safety-of-potent-platelet-p2y12-receptor-inhibitors-in-elderly-versus-nonelderly-patients-with-acute-coronary-syndrome-a-systematic-review-and-meta-analysis
#8
Giuseppe Tarantini, Daisuke Ueshima, Gianpiero D'Amico, Giulia Masiero, Giuseppe Musumeci, Gregg W Stone, Sorin J Brener
BACKGROUND: The use of the potent oral P2Y12 inhibitors prasugrel and ticagrelor in patients with acute coronary syndromes (ACS) has a favorable net clinical effect compared with clopidogrel and is recommended as first-line therapy. However, the impact of these agents on ischemic and bleeding events in elderly ACS patients is not well defined. METHODS: We performed a systematic review of articles comparing potent P2Y12 inhibitors to clopidogrel in elderly and nonelderly patients (defined according to each study) with ACS in terms of efficacy (composite of cardiovascular death, myocardial infarction, or stroke) and safety (major bleeding) end points...
January 2018: American Heart Journal
https://www.readbyqxmd.com/read/29222628/one-year-clinical-effectiveness-comparison-of-prasugrel-with-ticagrelor-results-from-a-retrospective-observational-study-using-an-integrated-claims-database
#9
Mark B Effron, Kavita V Nair, Cliff Molife, Stuart Y Keller, Robert L Page, Jason C Simeone, Brian Murphy, Beth L Nordstrom, Yajun Zhu, Patrick L McCollam, George W Vetrovec
BACKGROUND: No direct comparisons of ticagrelor and prasugrel with 1-year clinical follow-up have been reported. OBJECTIVES: Our objective was to compare 1-year clinical outcomes among patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) and treated with either ticagrelor or prasugrel in a real-world setting. METHODS: This retrospective study included patients from a payer database who were aged ≥18 years and had ACS managed with PCI with no history of transient ischemic attack (TIA)/stroke...
December 8, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29219758/the-use-of-alternatives-to-clopidogrel-in-flow-diversion-treatment-with-the-pipeline-embolization-device
#10
Elias Atallah, Hassan Saad, Kimon Bekelis, Nohra Chalouhi, Stavropoula Tjoumakaris, David Hasan, Jorge Eller, David Stidd, Robert H Rosenwasser, Pascal Jabbour
OBJECTIVE Thromboembolic complications continue to be encountered with Pipeline embolization devices (PEDs) despite routine clopidogrel/aspirin antiplatelet therapy. This study examined the safety and efficacy of prasugrel in the management of clopidogrel-resistant patients treated for cerebral aneurysms. METHODS Four hundred thirty-seven consecutive patients were identified between January 2011 and May 2016. Patients allergic, or having less than 30% platelet inhibition, to a daily 75-mg dose of clopidogrel received 10 mg of prasugrel daily (n = 20) or 90 mg of ticagrelor twice daily (n = 2)...
December 8, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29215418/switching-from-ticagrelor-or-prasugrel-to-clopidogrel
#11
James J Nawarskas, Tiffany N Montoya
Ticagrelor and prasugrel are newer antiplatelet drugs which, like clopidogrel, block the P2Y12 platelet receptor in order to inhibit platelet aggregation. Compared to clopidogrel, ticagrelor and prasugrel both have greater clinical efficacy but also have a higher risk of bleeding and are much more costly. Therefore, some institutions and providers switch patients from ticagrelor or prasugrel to clopidogrel in an effort to lower bleeding risk, stem costs, or otherwise ensure that patients can safely adhere to long-term P2Y12 inhibitor therapy...
December 5, 2017: Cardiology in Review
https://www.readbyqxmd.com/read/29192896/superior-early-periprocedural-efficacy-of-prasugrel-over-ticagrelor-in-patients-after-stenting
#12
Victor L Serebruany, Elena Z Golukhova, Naida I Bulaeva
No abstract text is available yet for this article.
November 30, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/29191640/incidence-of-visible-haematuria-among-antithrombotic-agents-a-systematic-review-of-over-175-000-patients
#13
Nikita R Bhatt, Niall F Davis, William J Nolan, Robert J Flynn, T E D McDermott, Arun Z Thomas, Rustom P Manecksha
OBJECTIVE: To determine the probability of visible haematuria with antithrombotic agents and to evaluate association of urological etiology in antithrombotic-related haematuria METHODS: PRISMA guidelines were followed to conduct a systematic review using search engines PUBMED and SCOPUS with the terms "(haematuria) OR (haematuria) OR urinary bleeding)) AND ((anticoagulants) OR anticoagulation) OR noac) OR novel anticoagulants) OR antiplatelet) OR dabigatran) OR rivaroxaban) OR apixaban) OR warfarin) OR aspirin) OR heparin) OR dipyridamole)"...
November 27, 2017: Urology
https://www.readbyqxmd.com/read/29189828/-coronary-revascularization-in-patients-with-st-elevation-myocardial-infarction-and-multivessel-disease
#14
Giulia Bugani, Valerio Lanzillotti, Elisa Filippini, Giuseppe Di Pasquale, Gianluca Campo
Forty to 60% of ST-elevation myocardial infarction (STEMI) patients present with multivessel coronary artery disease, identified during primary percutaneous coronary intervention (pPCI) of the culprit lesion. At present, data about revascularization of non-culprit coronary lesions are conflicting. Nevertheless, patients with multivessel coronary artery disease have a worse outcome. Recently, several randomized controlled trials and meta-analyses compared a strategy of culprit-only revascularization vs complete revascularization (during pPCI or staged PCI of the non-culprit lesion)...
December 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/29188812/antiplatelet-therapy-similar-1-year-results-for-prasugrel-and-ticagrelor
#15
Karina Huynh
No abstract text is available yet for this article.
November 30, 2017: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/29185103/unraveling-the-interaction-of-aspirin-ticagrelor-and-rosuvastatin-on-the-progression-of-atherosclerosis-and-inflammation-in-diabetic-mice
#16
Yumei Ye, Sven Nylander, Yochai Birnbaum
PURPOSE: We explored the effects of rosuvastatin, aspirin, ticagrelor, and clopidogrel, alone or in combinations on the progression of atherosclerosis and inflammasome activation in diabetic mice. Statins and ticagrelor increase the production of 15-epi-lipoxin A4 via cyclooxygenase-2. Aspirin alone increases 15-epi-lipoxin A4, but when combined with statins, cyclooxygenase-2 is completely blocked. METHODS: ApoE-/-/db+/db+ double-knockout mice received rosuvastatin (5 mg/kg/day), aspirin (25 mg/kg/day), ticagrelor (300 mg/kg/day), clopidogrel (75 mg/kg/day), or their combination for 14 weeks...
November 28, 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/29179275/-clinical-effectiveness-and-safety-of-ticagrelor-in-patients-after-pci-because-of-acute-non-st-segment-elevation-myocardial-infarction
#17
M Ye, X F Wang, P Jia, Y J Zeng
Objective: To observe the clinical effectiveness and safety of ticagrelor in patients after percutaneous coronary intervention (PCI) because of acute non ST segment elevation myocardial infarction (NSTEMI) in China. Methods: A total of 240 patients with NSTEMI were analyzed retrospectively from Beijing Anzhen hospital between Jan 2013 and Jan 2015, with 113 patients in the clopidogrel group, 127 in the ticagrelor group. ADP-induced platelet aggregation was investigated 1, 3 and 6 month later after PCI, and major adverse cardiac events (MACE) and thrombolysis in myocardial infarction (TIMI) bleeding were followed-up for 6 months...
November 21, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29173606/antiplatelet-effect-of-different-loading-doses-of-ticagrelor-in-patients-with-non-st-elevation-acute-coronary-syndrome-undergoing-percutaneous-coronary-intervention-the-apelot-trial
#18
RANDOMIZED CONTROLLED TRIAL
Hui-Liang Liu, Yu-Jie Wei, Peng Ding, Jiao Zhang, Tian-Chang Li, Bing Wang, Ming-Sheng Wang, Yun-Tian Li, Jian-Jun Zhang, Yi-Hong Ren, Qiang Tang, Jian-Ping Luo, Sheng-Li Yang, Hong-Yu Ma, Ying Liu, Wei Han, Yi Li, Zhi-Geng Jin, Li-Min Jin
BACKGROUND: We hypothesized that a high ticagrelor loading dose (LD) may improve platelet inhibition in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI). METHODS: This interventional multicentre open-label trial randomized 278 patients with NSTE-ACS to a high (360 mg) or conventional (180 mg) ticagrelor LD. The primary outcome was the platelet reactivity index (PRI) 1 hour after administration of the LD...
December 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/29172822/antithrombotic-efficacy-of-bivalirudin-compared-to-unfractionated-heparin-during-percutaneous-coronary-intervention-for-acute-coronary-syndrome
#19
Corinne Frere, Marc Laine, Gilles Lemesle, Pierre-Emmanuel Morange, Franck Paganelli, Francoise Dignat-George, Noemie Resseguier, Regis Guieu, Laurence Camoin-Jau, Laurent Bonello
Bivalirudin is associated with an increased risk of acute stent thrombosis (AST) compared to unfractionated heparin (UFH) in acute coronary syndrome patients (ACS) during short-duration percutaneous coronary intervention (PCI). The mechanisms involved are unknown. We aimed to investigate the antithrombotic efficacy of bivalirudin compared to UFH during PCI. In a monocenter study, we prospectively enrolled 30 patients undergoing PCI for a non-ST elevation ACS. They were randomly assigned to a single intravenous (IV) bolus of UFH (70 IU/kg) or an IV bolus of bivalirudin 0...
November 27, 2017: Platelets
https://www.readbyqxmd.com/read/29171876/decreased-platelet-inhibition-by-p2y12-receptor-blockers-in-anemia
#20
Patricia P Wadowski, Christoph W Kopp, Renate Koppensteiner, Irene M Lang, Joseph Pultar, Silvia Lee, Constantin Weikert, Simon Panzer, Thomas Gremmel
BACKGROUND: Anemic patients undergoing angioplasty and stenting are at an increased risk of ischemic events, which may be caused by an inadequate response to antiplatelet therapy with adenosine diphosphate (ADP) P2Y12 inhibitors. In the current study, we investigated the associations between anemia and on-treatment platelet reactivity in clopidogrel- (group 1, n=306) and prasugrel-/ticagrelor-treated (group 2, n=109) patients undergoing elective and acute angioplasty with stent implantation, respectively...
November 24, 2017: European Journal of Clinical Investigation
keyword
keyword
3908
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"